share_log

和黃醫藥:和黃醫藥宣佈Fruquintinib用於治療轉移性結直腸癌的FRESCO-2全球III期研究達到主要終點

HUTCHMED: HUTCHMED Announces that Fruquintinib Global Phase III FRESCO-2 Study Has Met Its Primary Endpoint in Metastatic Colorectal Cancer

Aug 7, 2022 20:00
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more